Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04213326 · ClinicalTrials.gov registry record

Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing

A clinical trial of Early Cancer Detection, sponsored by Exact Sciences Corporation.

Completed
Registry status
6,400
Enrollment target
14
Study locations

NCT04213326: Completed study of Early Cancer Detection, sponsored by Exact Sciences Corporation.

NCT04213326 is a study of Early Cancer Detection that has completed, run by Exact Sciences Corporation. The registered enrollment target is 6,400 participants. The trial reports 14 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04213326, a study of Early Cancer Detection, has completed, sponsored by Exact Sciences Corporation.

COMPLETED
Registry status
6,400 participants
Enrollment target
14
Study locations

Study Summary

This is a prospective, observational study of 1,000 subjects with known or suspected cancer and 2,000 subjects with no known cancer. Potential participants will be asked questions to confirm their eligibility by a nurse navigator, study staff member, or physician. Informed consent will be carried out for eligible subjects in accordance with applicable federal regulations and International Council for Harmonisation (ICH)/Good Clinical Practice (GCP) guidelines. Subjects will then complete a survey, and study staff will draw 60 mL of blood and measure the height and weight of the subject. Where available, data from the medical records of the cancer subjects will reviewed and collected. In addition, non-cancer subjects will be requested to allow access to their medical records as an optional portion of their informed consent.

Conditions Studied

Study Locations (14)

Florida

  • Sarah Cannon - Fort Walton Beach
  • Sarah Cannon - Ocala
  • Sarah Cannon - Pensacola

Georgia

  • Sarah Cannon - Augusta
  • Sarah Cannon - Macon
  • Sarah Cannon - Savannah

Kansas

  • Sarah Cannon - Kansas City
  • Sarah Cannon - Overland Park

California

  • Sarah Cannon - Thousand Oaks

Colorado

  • Sarah Cannon - Denver

Missouri

  • Sarah Cannon - Independence

Nevada

  • Sarah Cannon - Las Vegas

Tennessee

  • Sarah Cannon - Nashville

Trial Details

FieldValue
Enrollment Target 6,400 participants
Start Date 2019-11-18
Est. Completion 2021-01-29

Sponsor

Exact Sciences Corporation

30 total trials

What the Registry Record Tells You About NCT04213326

The ClinicalTrials.gov registry entry for NCT04213326 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6,400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exact Sciences Corporation, which has 30 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Early Cancer Detection appearing as the primary indexed condition, and to 0 interventions.

NCT04213326 reports 14 study locations spanning 9 distinct geographic areas - top geographies include Florida, Georgia, Kansas.

Frequently Asked Questions

What is clinical trial NCT04213326 about?

NCT04213326 is a clinical study titled "Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing". This is a prospective, observational study of 1,000 subjects with known or suspected cancer and 2,000 subjects with no known cancer. Potential participants will be asked questions to confirm their eligibility by a nurse navigator, study staff member, or physician. Informed consent will be carried ...

What is the current status of trial NCT04213326?

This trial is currently completed. The enrollment target is 6,400 participants. The study started on 2019-11-18. Estimated completion is 2021-01-29.

What conditions does trial NCT04213326 study?

This clinical trial studies the following conditions: Early Cancer Detection.

Who is sponsoring clinical trial NCT04213326?

This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04213326 being conducted?

This trial has 14 study locations across California, Colorado, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Early Cancer Detection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.